Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnsellASX:ANN +0.41%77 EV-to-EBITDA is 11.67 as of Jul. 16, 2026, which is 9% below its 10-year median of 12.77. GuruFocus rates ASX:ANN with a GF Score™ of 77/100 and a GF Value™ of A$29.29 (Fairly Valued). The stock has 4 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Ansell ranks better than 60.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ansell's enterprise value is A$5,365 Mil.
Ansell's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$460 Mil. Therefore, Ansell's EV-to-EBITDA for today is 11.67.
The historical rank and industry rank for Ansell's EV-to-EBITDA or its related term are showing as below:
ASX:ANN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6 Med: 12.77 Max: 17.41
Current: 11.66
During the past 13 years, the highest EV-to-EBITDA of Ansell was 17.41. The lowest was 6.00. And the median was 12.77.
ASX:ANN's EV-to-EBITDA is ranked better than 60.86% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.23
vs ASX:ANN: 11.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-16), Ansell's stock price is A$31.91.
Ansell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.409. Therefore, Ansell's PE Ratio (TTM) for today is 22.65.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Ansell (ASX:ANN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ansell's share price for today is A$31.91.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ansell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.409.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ansell's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ANN vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Ansell's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ansell EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ansell's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ansell's EV-to-EBITDA falls into.
Ansell's current Enterprise Value is A$5,365 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ansell's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$460 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ansell (ASX:ANN) has a EV-to-EBITDA of 11.67 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ansell. This is near median its historical median of 12.77. Over the past decade, Ansell's EV-to-EBITDA has ranged from 6.00 to 17.41. According to the industry distribution chart, Ansell ranks #200 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 39.1%.
Is Ansell's EV-to-EBITDA too high?
Ansell's current EV-to-EBITDA of 11.67 is near median its 10-year median of 12.77. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 17.41. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.23. Ansell's value of 11.67 is 18% below this industry median. Based on the distribution chart, Ansell ranks #200 out of 511 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ansell has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ansell's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ansell ranks #200 out of 511 companies for EV-to-EBITDA. This puts Ansell in the upper half of its industry. The industry median EV-to-EBITDA is 14.23. Ansell's value of 11.67 is 18% below this benchmark. Historically, Ansell's own EV-to-EBITDA has ranged from 6.00 to 17.41 over the past decade. While the company's 10-year median is 12.77 vs. the industry median of 14.23, Ansell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.23, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ansell's current EV-to-EBITDA of 11.67 is 18% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ansell. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ansell's current EV-to-EBITDA is 11.67, which is near median its own 10-year median of 12.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ansell stock overvalued right now?
Based on GuruFocus' analysis, Ansell (ASX:ANN) is currently considered Fairly Valued. The stock's GF Value™ is A$29.29, compared to a current price of A$31.91 — trading 8.9% above its estimated fair value. The current EV-to-EBITDA is 11.67, which is near median its 10-year median of 12.77 and 18% below the Medical Devices & Instruments industry median of 14.23. Ansell's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ansell (ASX:ANN), the current EV-to-EBITDA is 11.67 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ansell (ASX:ANN) Overvalued in 2026?
Based on GuruFocus' analysis, Ansell stock appears to be overvalued.
The current stock price of A$31.91 is trading 8.9% above its estimated GF Value™ of A$29.29.
GuruFocus considers Ansell to be Fairly Valued.
Key valuation signals for ASX:ANN:
EV-to-EBITDA: 11.67 (near median its 10-year median of 12.77)
GF Value™: A$29.29 vs. price of A$31.91 (8.9% above fair value)
Industry Position: 18% below the Medical Devices & Instruments median (#200 of 511)
No single metric tells the full story. See the ASX:ANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 55% of revenue and operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents, and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly. Largest sales regions are North America and Europe, Middle East, and Africa. Asia-Pacific and Latin America, combined, are about one-fourth of sales.
77GF Score
Get the complete analysis for ASX:ANN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ANN has been successfully added to your 
